Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells

Journal of Nuclear Medicine

Volumn 44, Issue 5, 2003, Pages 823-831

  Hoffman, Timothy J ^a,b   Gali, Hariprasad ^b   Smith, C Jeffrey ^b   Sieckman, Gary L ^a   Hayes, Donald L ^b   Owen, Nellie K ^b   Volkert, Wynn A ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

111In; Bombesin; Gastrin releasing peptide; Prostate cancer

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BOMBESIN DERIVATIVE; GASTRIN RELEASING PEPTIDE; INDIUM 111; RADIOPHARMACEUTICAL AGENT; BOMBESIN RECEPTOR; DIAGNOSTIC AGENT; INDIUM;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOACTIVITY; STRUCTURE ANALYSIS; ANIMAL; CELL CULTURE; FEMALE; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; MOUSE MUTANT; PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MALE; MICE; MICE, INBRED ICR; MICE, SCID; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0037945450     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 99mTc-labelled peptide-based radiopharmaceuticals an overview. Nucl Med Commun. 1999;20:1093-1112
2. Hoffman TJ, Quinn TP, Volkert WA. Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl Med Biol. 2001; 28:527-539.
3. Anastasia A, Erspamer V, Bucci H. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia. 1971;27:166-168.
4. 14] bombesin(6-14). Clin Cancer Res 2002;8: 1139-1146.
5. Qin Y, Ertl T, Cai R-Z, Halmos G, Schally AV Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res. 1994;54:1035-1041
6. 13, 14] Bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Life Sci. 1985;37:105-113.
7. Coy DH, Jensen RT, Jiang NY. Systematic development of bombesin/gastrin-releasing peptide antagonists. J Natl Cancer Inst Monogr. 1992;13:133-139
8. Moody TW. Review, peptides and growth factors in non-small cell lung cancer. Peptides. 1996;17:545-555.
9. 4)-bombesin by tumor cells Prostate. 1994;25:29-38.
10. 4-bombesin with specific receptors on normal human pancreatic membranes. Regul Pept. 1986; 13:125-132.
11. Van de Wiele C, Dumont F, Broecke RV, et al Technetium-99m RP525, a GRP analogue for visualization of GRP receptor-expressing malignancies: a feasibility study Eur J Nucl Med 2000;27:1694-1699.
12. Hoffman TJ, Sieckman GL, Volkert WA. Targeting small cell lung cancer using iodinated peptide analogues. J Labelled Compds Radiopharm. 1995;37:321-325.
13. Hoffman TJ, Sieckman GL, Volkert WA. Iodinated bombesin analogs: effect of a N-terminal vs. side chain iodine attachment of BBN/GRP receptor binding [abstract]. J Nucl Med. 1996;37(suppl):185P.
14. 105Rh labeled bombesin analogues: enhancement of GRP receptor binding affinity utilizing aliphatic carbon chain linkers. J Labelled Compds Radiopharm. 1997;40:490-493.
15. 99mTc labelling and in vivo studies of a bombesin analog with a novel water-soluble bifunctional chelating agent. Bioconjug Chem. 1999;10:254-260.
16. Hoffman TJ, Simpson SD, Smith CJ, et al. Accumulation and retention of Tc-99m RP527 by GRP receptor expressing tumors in scid mice [abstract]. J Nucl Med. 1999;40(suppl) 104P.
17. 99mTc-GRP receptor targeting peptides using multi-amino acid linking groups [abstract]. J Nucl Med. 2000;41(suppl).228P.
18. 2 a new gastrin releasing peptide receptor (GRPr) targeting radiopharmaceutical J Labelled Compds Radiopharm. 2001;44(suppl):706-708.
19. Safavy A, Khazaeli MB, Qin H, Buchsbaum DJ. Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer Suppl 1997;80:2354-2359.
20. Baidoo KE, Lin KS, Zhan Y, Finley P, Scheffel U, Wagner HN Jr. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem. 1998;9:218-225.
21. Breeman WAP, Hofland LJ, DeJong M, et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999;81:658-665.
22. 4]bombesin, a new radioligand for bombesin-receptor scintigraphy Int J Cancer. 1999;83:657-663.
23. 99mTc-diaminedithiol analog of bombesin [abstract]. J Nucl Med. 2000;41(suppl):40P.
24. 64Cu-labeled bombesin analogue for diagnosis of gastrin-releasing peptide receptor positive tumors by microPET imaging. J Labelled Compds Radiopharm. 2001;44(suppl): S81-S83.
25. Bijsterbosch MK. Selective drug delivery by means of receplor-mediated endocytosis. Q J Nucl Med 1995;39:4-9.
26. Fraser CM Structural and functional analysis of G protein-coupled receptors and potential diagnostic ligands J Nucl Med 1995;36(suppl):17S-21S
27. Harden TK, Boyer JL, Dougherty RW. Drug analysis based on signaling responses to G-protein-coupled receptors. In. Left P, ed. Receptor-Based Drug Design. New York, NY: Marcel Dekker, Inc; 1998:79-105.
28. Behr TM, Goldenberg DM. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides. J Nucl Med. 1996;37:834-836
29. Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem. 2001;12:7-34
30. 111indium-DOTA chelates: a simple and efficient method Bioconjug Chem. 1994;5:101-104.
31. Cutler CS, Smith CJ, Ehrhardt GJ, Tyler TT, Jurisson SS, Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm 2000;15:531-545.
32. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-371.
33. Heppeler A, Froidevaux S, Macke HR, et al. Radiometal-labelled macrocyclic chelator derivatized somatostatin analogue with superb tumor targeting properties and potential for receptor mediated internal radiotherapy. Chem Eur J. 1999;5: 1974-1981
34. Lister-James J, Moyer BR, Dean RT. Pharmacokinetic considerations in the development of peptide-based imaging agents. Q J Nucl Med 1997;41:111-118.
35. Beck-Sickinger AG. Structural characterization and binding sites of G-protein-coupled receptors. Drug Discov Today, 1996;1:502-513.
36. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med. 1993;34:1728-1738.
37. Novak-Hofer I, Amstutz HP, Morgenthaler JJ, Schubiger PA. Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells. Int J Cancer. 1994;57:427-432.
38. Arano Y. Strategies to reduce renal radioactivity levels of antibody fragments Q J Nucl Med 1998;42:262-267.
39. Chen J, Chen Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000;60:5649-5658.
40. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev. 1999; 99:2269-2292